| |
Molecular Oncology highlights new discoveries, approaches, as well as technical developments, in basic, clinical and discovery-driven
translational research. Topics include:
• Key biological processes such as cell cycle; DNA repair; apoptosis; invasion and
metastasis; angiogenesis and lymphangiogenesis; cell signalling and interactive networks; immune response.
• Emerging technologies
(genomics, proteomics, functional genomics, metabolomics, tissue arrays, imaging), and model systems.
•Biomarkers: diagnosis,
prognosis, stratification and efficacy.
• Cancer genetics, epigenetics, and genomic instability.
• Minimal residual
disease, pre-malignant lesions.
• Cancer micro-environment.
• Molecular pathology.
• Tumour immunology.
• Translational research.
• Cancer therapy (target discovery, drug design, immunotherapy, combination therapies, resistance,
and individualised treatment).
• Chemotherapy, radiotherapy and surgery.
• Clinical pharmacology.
• Clinical
trials, integration of basic science into cancer clinical trials.
• Epidemiology and prevention.
• Infrastructures
(biobanks, databases, genomic resources).
A main feature of the Journal is to provide an international forum for debating cancer
issues, and for integrating the input of all the stakeholders.
Coverage: Reviews, original articles, technical notes, editorials,
news & views (commentary, science policy issues, ethical and legal issues, patient organisations, industry needs and alliances, regulatory
issues, news items), letters to the editor, conference announcements, advertisements.
Submitting Authors:
Manuscripts can
be submitted to Molecular Oncology at:
 http://ees.elsevier.com/molonc/
|
| |
|
|
